Integrated chemical manufacturer Epigral Limited saw a 37.9% decrease in its consolidated net profit to Rs 99.7 crore in the first quarter of FY27, down from Rs 160.7 crore in Q1 FY26. Despite this decline, the company’s revenue from operations rose by 16.3% year-on-year to Rs 705.4 crore during the April-June quarter.
Maulik Patel, Chairman and Managing Director of Epigral Limited, commented on the results, noting the steady growth achieved in Q1 FY27 amidst significant macroeconomic volatility due to geopolitical tensions in West Asia. He highlighted challenges such as fluctuating raw material prices, increased freight costs, and shipment delays during the quarter.
The company’s Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 9.7% to Rs 179.2 crore compared to Rs 163.4 crore in the previous year. However, the EBITDA margin slightly narrowed to 25.4% from 26.9% in the corresponding quarter of the last fiscal year, as indicated in its regulatory filing.
Epigral Limited’s board approved its foray into the epoxy resin and formulations business, with plans to establish a production capacity of 1,25,000 tonnes per annum (TPA). This strategic move, including the setup of a Multi-Purpose Plant (MPP), is expected to require an estimated capital expenditure of around Rs 600 crore. The company aims to commission both facilities during the second half of FY28.
The expansion into epoxy resin and formulations signifies Epigral’s progression into the advanced materials and specialty chemicals sector, catering to various industries such as construction, renewable energy, automotive, electronics, infrastructure, marine, aerospace, and semiconductors. Epoxy resin finds wide applications in wind turbine blades, industrial coatings, electrical insulation, and automotive components, among others. Epigral anticipates strong domestic demand driven by infrastructure development, manufacturing growth, and investments in renewable energy.
